Thinheal has formed excellent customer customization capabilities by leveraging its leading peptide synthesis technology (including a variety of solid-phase and liquid-phase synthesis methods), outstanding cost control advantages for bulk peptide products, and strict peptide product quality management
Thinheal's process development team focuses on the field of peptide API process development, with technology leadership as the core driver, providing customers with efficient and stable customized solutions. We have deeply cultivated solid phase synthesis (SPPS), liquid phase synthesis (LPPS) and continuous flow synthesis technologies, and have the ability to develop the entire process from milligram-level screening to 100-kilogram-level amplification. Through the independently built peptide green chemistry technology platform, we have overcome the bottleneck of difficult sequence synthesis, significantly improved product purity and yield, and met the high activity requirements of innovative drugs such as anti-tumor and metabolic diseases.
The production system strictly follows cGMP standards, equipped with fully automatic synthesis equipment and advanced analytical instruments (such as UPLC, high-resolution mass spectrometry), combined with self-developed process optimization models to ensure process robustness and batch consistency. The company has completed a number of complex peptide API process development projects, covering preclinical to commercial production stages, and empowers global pharmaceutical companies to accelerate drug development with its rapid response and data-driven service advantages.
